Published in BMC Med Genet on December 20, 2007
The metabolic syndrome. Endocr Rev (2008) 5.33
Genetic determinants of plasma triglycerides. J Lipid Res (2010) 1.63
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology (2011) 1.21
Meta-analysis of the INSIG2 association with obesity including 74,345 individuals: does heterogeneity of estimates relate to study design? PLoS Genet (2009) 1.18
Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China. Lipids Health Dis (2011) 1.02
Interactions of the apolipoprotein C-III 3238C>G polymorphism and alcohol consumption on serum triglyceride levels. Lipids Health Dis (2010) 1.02
Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population. Lipids Health Dis (2014) 0.87
Polymorphisms in Fas gene is associated with HIV-related lipoatrophy in Thai patients. AIDS Res Hum Retroviruses (2012) 0.80
Effect of apolipoprotein C3 genetic polymorphisms on serum lipid levels and the risk of intracerebral hemorrhage. Lipids Health Dis (2015) 0.80
Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. World J Gastroenterol (2014) 0.79
Genetic association study with metabolic syndrome and metabolic-related traits in a cross-sectional sample and a 10-year longitudinal sample of chinese elderly population. PLoS One (2014) 0.77
Apolipoprotein C3 polymorphisms, cognitive function and diabetes in Caribbean origin Hispanics. PLoS One (2009) 0.77
Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol (2015) 0.75
The metabolic syndrome. Lancet (2005) 19.47
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med (2006) 18.51
A common genetic variant is associated with adult and childhood obesity. Science (2006) 14.95
Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci U S A (2002) 3.51
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science (1990) 3.04
SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol (2002) 2.12
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest (1995) 2.05
Comment on "A common genetic variant is associated with adult and childhood obesity". Science (2007) 2.04
Comment on "A common genetic variant is associated with adult and childhood obesity". Science (2007) 1.93
Comment on "A common genetic variant is associated with adult and childhood obesity". Science (2007) 1.86
Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med (2006) 1.55
Genetics of the metabolic syndrome. Br J Nutr (2000) 1.53
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res (2003) 1.41
INSIG-2 promoter polymorphism and obesity related phenotypes: association study in 1428 members of 248 families. BMC Med Genet (2006) 1.39
APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res (2007) 1.22
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol (1998) 1.22
Inuit health in Greenland: a population survey of life style and disease in Greenland and among Inuit living in Denmark. Int J Circumpolar Health (2003) 1.16
Contribution of apolipoprotein C-III gene variants to determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol (2000) 1.12
Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis (2006) 1.11
Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol (1997) 0.93
The Gly16-->Arg16 and Gln27-->Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab (2003) 0.91
Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis (2000) 0.89
Genetic forms of the cardiometabolic syndrome: what can they tell the clinician? J Cardiometab Syndr (2007) 0.83
Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. J Clin Invest (1997) 0.82
The Keewatin Health Assessment Study, NWT, Canada. Arctic Med Res (1993) 0.81
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med (2013) 9.66
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA (2003) 5.18
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J (2007) 4.88
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med (2009) 4.80
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53
Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet (2008) 4.37
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32
Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27
Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21
Reconstructing angina: cardiac symptoms are the same in women and men. JAMA Intern Med (2013) 3.97
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med (2005) 3.92
Indigenous health in the Arctic: an overview of the circumpolar Inuit population. Scand J Public Health (2004) 3.88
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res (2006) 3.80
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J (2008) 3.52
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43
Hypertriglyceridemia: its etiology, effects and treatment. CMAJ (2007) 3.42
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J (2008) 3.38
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33